Tue, Sep 16, 2014, 6:04 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • bigbro79 bigbro79 Oct 21, 2013 9:02 PM Flag

    Renz interview withe Bioworld Today in August -

    “We don’t really have anything to talk about right now, so we’re not going to discuss adverse events
    or discontinuation rates, but everything is consistent with what we thought it would be, so far,” said Renz, calling the drug well tolerated, with no severe adverse events"

    We do believe that we’re sitting on a potential blockbuster,” Renz said, especially if Z160 can get the job
    done without side effects, which can be nasty with pain drugs. “The cover-up is worse than the crime, sometimes,” he said. “The goal is to keep going [with trials] as far as we can, but we expect solicitation from all the major pain players and the major specialty pharmaceutical companies
    that focus on pain,” he said. “They’re all aware of our program, and they’ve all asked us to call them fi rst when the data come in. We believe a partnership will be the ultimate outcome.”

    I think we have a winner here !!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.180.00(0.00%)Jul 15 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.